|
Daily Medical Update
Psoriasis
Sunday, June 28, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Medical sciences (Basel, Switzerland) (2026) - Systematic Review
Key Findings
- Across 11 comparative studies, biologics improved generalized pustular psoriasis activity and reduced flare burden.
- IL-36 inhibition with spesolimab achieved pustular clearance within 1 week and reduced recurrent flares over follow-up.
📋 Practice Implication: For acute generalized pustular psoriasis flares, early IL-36 blockade is the strongest evidence-based monotherapy when rapid disease control is the priority.
|
Journal of the European Academy of Dermatology and Venereology : JEADV (2025) - Meta-Analysis
Key Findings
- Weight-loss interventions reduced PASI more than control care, with a pooled mean difference of -2.5 points.
- Patients in weight-loss programs improved PASI75 response (risk ratio 1.6) and improved dermatology quality-of-life scores.
📋 Practice Implication: When psoriasis coexists with overweight or obesity, structured weight-loss treatment should be incorporated because it improves both skin outcomes and patient-reported quality of life.
|
Journal of the European Academy of Dermatology and Venereology : JEADV (2025) - Network Meta-Analysis
Key Findings
- All studied biologics significantly improved PASI75 and PASI90 response rates versus placebo in moderate-to-severe pediatric plaque psoriasis.
- Ixekizumab improved complete clearance rankings for PASI100, while secukinumab and ustekinumab improved PASI90, PASI75, and CDLQI 0/1 outcomes.
📋 Practice Implication: Biologic selection in pediatric plaque psoriasis can be tailored to the target outcome, with IL-17 agents favoring deeper clearance and ustekinumab favoring broader PASI75 and quality-of-life response.
|
Frontiers in immunology (2025) - Meta-Analysis
Key Findings
- In 18 studies with 342 patients, IL-17-targeted biologics delivered the highest PASI75 response rates, reaching 82% by week 16.
- IL-23-targeted biologics reduced adverse-event incidence to 5%, suggesting a safety advantage within this severe phenotype.
📋 Practice Implication: For erythrodermic psoriasis, biologics appear suitable for first-line systemic escalation, with IL-17 agents favored for faster clearance and IL-23 agents considered when tolerability is a dominant concern.
|
Medicine (2026) - Meta-Analysis
Key Findings
- Psoriasis was associated with an increased stroke hazard versus controls in 18 studies, with a pooled HR of 1.24.
- Stroke risk increased with disease severity, from HR 1.09 in mild psoriasis to HR 1.36 in severe psoriasis, and remained elevated across regions and age groups.
📋 Practice Implication: Psoriasis follow-up should include routine cardiovascular prevention work, especially in severe disease, because stroke risk remains elevated even after adjustment in observational cohorts.
|
|
💡
Summary
Recent psoriasis evidence supports phenotype-specific systemic therapy, with IL-36 blockade standing out for generalized pustular psoriasis and biologics showing meaningful benefit in pediatric plaque and erythrodermic disease. Adjunctive weight-loss programs improved skin severity and quality of life, while psoriasis remained linked to higher stroke risk, reinforcing the need to pair skin control with cardiometabolic risk management.
|
|